Soligenix (SNGX) EPS (Basic) Growth (1y) (2012 - 2026)
Soligenix (SNGX) EPS (Basic) Growth (1y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.66 Bn | 131.80 Bn | 2.84 Bn | 7.74% |
| 2 | Regeneron Pharmaceuticals | 86.52 Bn | 78.53 Bn | 3.93 Bn | -4.72% |
| 3 | Argenx Se | 65.33 Bn | 60.14 Bn | 1.37 Bn | 88.81% |
| 4 | Moderna | 59.76 Bn | 54.62 Bn | 52.00 Mn | 7.59% |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn | 143.95% |
| 6 | Alnylam Pharmaceuticals | 31.84 Bn | 28.53 Bn | 992.69 Mn | 322.67% |
| 7 | BioNTech SE | 28.23 Bn | 9.84 Bn | 668.28 Mn | -147.33% |
| 8 | Insmed | 27.52 Bn | 26.36 Bn | 358.27 Mn | 96.41% |
| 9 | Royalty Pharma | 27.29 Bn | 26.46 Bn | - | -16.29% |
| 10 | Soligenix | 6.34 Mn | 6.34 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 84.88% |
| Mar 31, 2026 | 71.28% |
| Dec 31, 2025 | 68.98% |
| Sep 30, 2025 | 25.07% |
| Jun 30, 2025 | 36.91% |
| Mar 31, 2025 | 66.77% |
| Dec 31, 2024 | 52.06% |
| Sep 30, 2024 | 69.56% |
| Jun 30, 2024 | 63.30% |
| Mar 31, 2024 | 49.27% |
| Dec 31, 2023 | 82.06% |
| Sep 30, 2023 | 86.10% |
| Jun 30, 2023 | 73.27% |
| Mar 31, 2023 | 76.39% |
| Dec 31, 2022 | 25.64% |
| Sep 30, 2022 | 12.87% |
| Jun 30, 2022 | -17.22% |
| Mar 31, 2022 | -57.92% |
| Dec 31, 2021 | 41.85% |
| Sep 30, 2021 | -45.62% |